The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-bacterial thiazole derivatives.

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Anti-bacterial thiazole derivatives is a key innovation area in pharmaceuticals

Thiazoles are five membered aromatic heterocycles containing sulphur and nitrogen atoms. Thiazoles and its derivatives have broad applications in drug development. Thiazole derivatives exhibit significant antibacterial activity against various bacteria and pathogens.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 170+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-bacterial thiazole derivatives.

Key players in anti-bacterial thiazole derivatives – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to anti-bacterial thiazole derivatives

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
Wockhardt 353 Unlock company profile
Merck & Co 331 Unlock company profile
Meiji Holdings 176 Unlock company profile
Shionogi & Co 139 Unlock company profile
Lionco Pharmaceutical Group 131 Unlock company profile
Melinta Therapeutics 122 Unlock company profile
Mutabilis 120 Unlock company profile
Pfizer 113 Unlock company profile
Bayer 104 Unlock company profile
Innoviva 91 Unlock company profile
Insmed 82 Unlock company profile
Zoetis 72 Unlock company profile
Basilea Pharmaceutica 71 Unlock company profile
ContraFect 68 Unlock company profile
VenatoRx Pharmaceuticals 67 Unlock company profile
Luoxin Pharmacy Group 65 Unlock company profile
GSK 54 Unlock company profile
Dhanuka Group 54 Unlock company profile
AlgiPharma 49 Unlock company profile
Novartis 48 Unlock company profile
Biogenic Innovations 48 Unlock company profile
Hainan Weikang Pharmaceutical (Qianshan) 48 Unlock company profile
RedHill Biopharma 46 Unlock company profile
Armata Pharmaceuticals 46 Unlock company profile
Elanco Animal Health 46 Unlock company profile
F. Hoffmann-La Roche 41 Unlock company profile
Helperby Therapeutics 37 Unlock company profile
Antabio 36 Unlock company profile
Summit Therapeutics 36 Unlock company profile
Techfields 32 Unlock company profile
CSPC Pharmaceutical Group 32 Unlock company profile
Venus Remedies 29 Unlock company profile
Otonomy 28 Unlock company profile
Sarepta Therapeutics 28 Unlock company profile
Guangzhou Baiyunshan Pharmaceutical Holdings 25 Unlock company profile
Sun Pharmaceutical Industries 25 Unlock company profile
Nuance Biotech 25 Unlock company profile
Lamellar Biomedical 25 Unlock company profile
Advanced Scientific Developements 24 Unlock company profile
Fedora Pharmaceuticals 23 Unlock company profile
Daiichi Sankyo 23 Unlock company profile
Xiangbei Welman Pharmaceutical 22 Unlock company profile
Children's Medical Center 22 Unlock company profile
Inflammatory Response Research 21 Unlock company profile
C. H. Boehringer Sohn 21 Unlock company profile
AbbVie 20 Unlock company profile
Fosun Holdings 19 Unlock company profile
NAEJA-RGM Pharmaceuticals 19 Unlock company profile
Qpex Biopharma 18 Unlock company profile
Spero Therapeutics 18 Unlock company profile

Source: GlobalData Patent Analytics

Wockhardt is one of the leading patent filers for anti-bacterial thiazole derivatives. Its product portfolio caters to various therapeutic areas including orthopaedics, dental care, dermatology, rheumatology, gynaecology, paediatrics, cardiology, pain management, nephrology, neurology, and diabetes. The company also concentrates its research in new chemical entities (NCE), generics, abbreviated new drug applications (ANDAs), biosimilars, novel drug delivery systems (NDDS).

In terms of application diversity, Mackay Memorial Hospital is the top company, followed by Theravance Biopharma and Wakunaga Pharmaceutical. By means of geographic reach, Fedora Pharmaceuticals holds the top position, while Lamellar Biomedical and Antabio are in the second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.